Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Does use of the adjuvant! model influence use of adjuvant therapy through better risk communication?

Belkora JK, Hutton DW, Moore DH, Siminoff LA.

J Natl Compr Canc Netw. 2011 Jul 1;9(7):707-12.

2.

Oncologist use of the Adjuvant! model for risk communication: a pilot study examining patient knowledge of 10-year prognosis.

Belkora JK, Rugo HS, Moore DH, Hutton DW, Chen DF, Esserman LJ.

BMC Cancer. 2009 Apr 28;9:127. doi: 10.1186/1471-2407-9-127.

3.
4.

A decision aid to assist in adjuvant therapy choices for breast cancer.

Siminoff LA, Gordon NH, Silverman P, Budd T, Ravdin PM.

Psychooncology. 2006 Nov;15(11):1001-13.

PMID:
16511899
6.

Improving local control with breast-conserving therapy: a 27-year single-institution experience.

Cabioglu N, Hunt KK, Buchholz TA, Mirza N, Singletary SE, Kuerer HM, Babiera GV, Ames FC, Sahin AA, Meric-Bernstam F.

Cancer. 2005 Jul 1;104(1):20-9.

7.

Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.

Johansson P, Fohlin H, Arnesson LG, Dufmats M, Nordenskjöld K, Nordenskjöld B, Stål O; South-East Sweden Breast Cancer Study Group..

Acta Oncol. 2009;48(4):504-13. doi: 10.1080/02841860902718754.

PMID:
19235568
8.

Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: an update. Ontario Clinical Oncology Group.

Clark RM, Whelan T, Levine M, Roberts R, Willan A, McCulloch P, Lipa M, Wilkinson RH, Mahoney LJ.

J Natl Cancer Inst. 1996 Nov 20;88(22):1659-64.

PMID:
8931610
9.

Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.

Winter-Roach BA, Kitchener HC, Dickinson HO.

Cochrane Database Syst Rev. 2009 Jan 21;(1):CD004706. doi: 10.1002/14651858.CD004706.pub2. Review. Update in: Cochrane Database Syst Rev. 2009;(3):CD004706.

PMID:
19160239
10.

Ascertaining prognosis for breast cancer in node-negative patients with innovative survival analysis.

Chapman JA, Lickley HL, Trudeau ME, Hanna WM, Kahn HJ, Murray D, Sawka CA, Mobbs BG, McCready DR, Pritchard KI.

Breast J. 2006 Jan-Feb;12(1):37-47.

PMID:
16409585
11.

Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.

Winter-Roach BA, Kitchener HC, Dickinson HO.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD004706. doi: 10.1002/14651858.CD004706.pub3. Review. Update in: Cochrane Database Syst Rev. 2012;3:CD004706.

PMID:
19588360
12.

The consequence of undertreating breast cancer in the elderly.

Gajdos C, Tartter PI, Bleiweiss IJ, Lopchinsky RA, Bernstein JL.

J Am Coll Surg. 2001 Jun;192(6):698-707.

PMID:
11400963
13.

Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era.

Palmieri C, Shah D, Krell J, Gojis O, Hogben K, Riddle P, Ahmad R, Tat T, Fox K, Porter A, Mahmoud S, Kirschke S, Shousha S, Gudi M, Coombes RC, Leonard R, Cleator S.

Clin Breast Cancer. 2011 Apr;11(2):93-102. doi: 10.1016/j.clbc.2011.03.001. Epub 2011 Apr 11.

PMID:
21569995
14.

A systematic overview of chemotherapy effects in colorectal cancer.

Ragnhammar P, Hafström L, Nygren P, Glimelius B; SBU-group. Swedish Council of Technology Assessment in Health Care..

Acta Oncol. 2001;40(2-3):282-308. Review.

PMID:
11441937
15.

Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.

Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch C, Stierer M, Hofbauer F, Renner K, Dadak C, Rücklinger E, Samonigg H; Austrian Breast and Colorectal Cancer Study Group..

J Natl Cancer Inst. 2007 Dec 19;99(24):1845-53. Epub 2007 Dec 11. Erratum in: J Natl Cancer Inst. 2008 Feb 6;100(3):226.

PMID:
18073378
16.

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.

Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, Deschênes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AH, Feldman MI, Farrar W, Evans J, Lickley HL.

J Natl Cancer Inst. 1996 Nov 6;88(21):1529-42.

PMID:
8901851
17.

Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.

Damodaran SE, Pradhan SC, Umamaheswaran G, Kadambari D, Reddy KS, Adithan C.

Cancer Chemother Pharmacol. 2012 Jul;70(1):75-81. doi: 10.1007/s00280-012-1891-1. Epub 2012 May 24.

PMID:
22623212
18.

A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer.

Gelber RD, Goldhirsch A, Cole BF, Wieand HS, Schroeder G, Krook JE.

J Natl Cancer Inst. 1996 Aug 7;88(15):1039-45.

PMID:
8683634
19.

Patient age and cancer treatment decisions. Patient and physician views.

Kutner JS, Vu KO, Prindiville SA, Byers TE.

Cancer Pract. 2000 May-Jun;8(3):114-9.

PMID:
11898135
20.

Helping patients make informed choices: a randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer.

Whelan T, Sawka C, Levine M, Gafni A, Reyno L, Willan A, Julian J, Dent S, Abu-Zahra H, Chouinard E, Tozer R, Pritchard K, Bodendorfer I.

J Natl Cancer Inst. 2003 Apr 16;95(8):581-7.

PMID:
12697850

Supplemental Content

Support Center